tenax therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for patients who require treatment for various critical care conditions. our development portfolio includes novel product candidates that have the potential to address various critical care conditions with high unmet medical need.
Company profile
Ticker
TENX
Exchange
Website
CEO
John Kelley
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
OXYGEN BIOTHERAPEUTICS, INC., SYNTHETIC BLOOD INTERNATIONAL INC
SEC CIK
Corporate docs
Subsidiaries
Life Newco, Inc. • PHPrecisionMed Inc. ...
IRS number
262593535
TENX stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
15 Apr 24
EFFECT
Notice of effectiveness
15 Apr 24
POS AM
Prospectus update (post-effective amendment)
11 Apr 24
POS AM
Prospectus update (post-effective amendment)
11 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
28 Mar 24
424B3
Prospectus supplement
26 Feb 24
424B3
Prospectus supplement
26 Feb 24
8-K
Other Events
23 Feb 24
424B3
Prospectus supplement
21 Feb 24
Latest ownership filings
SC 13G
S.H.N. Financial Investments Ltd.
20 Feb 24
SC 13G
CVI Investments, Inc.
16 Feb 24
SC 13G
Lind Global Fund II LP
15 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
3
LAWRENCE R HOFFMAN
12 Jan 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G
INTRACOASTAL CAPITAL, LLC
13 Feb 23
SC 13D/A
Rich Stuart
9 Feb 23
SC 13D/A
Doogan Declan
9 Feb 23
SC 13D/A
Rich Stuart
6 Jan 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 11.14 mm | 11.14 mm | 11.14 mm | 11.14 mm | 11.14 mm | 11.14 mm |
Cash burn (monthly) | 750.81 k | (no burn) | (no burn) | 1.22 mm | 693.72 k | 586.84 k |
Cash used (since last report) | 5.11 mm | n/a | n/a | 8.32 mm | 4.72 mm | 4.00 mm |
Cash remaining | 6.03 mm | n/a | n/a | 2.82 mm | 6.42 mm | 7.15 mm |
Runway (months of cash) | 8.0 | n/a | n/a | 2.3 | 9.3 | 12.2 |
Institutional ownership, Q3 2023
67.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 18 |
Opened positions | 4 |
Closed positions | 3 |
Increased positions | 2 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 174.76 mm |
Total shares | 1.20 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Intracoastal Capital | 479.73 k | $840.00 k |
CI Private Wealth | 191.46 k | $56.45 mm |
Geode Capital Management | 118.98 k | $35.07 mm |
Two Sigma Securities | 97.04 k | $29.01 mm |
Stuart Rich | 95.48 k | $142.00 k |
STT State Street | 95.12 k | $28.04 mm |
VIRT Virtu Financial | 36.80 k | $11.00 k |
BLK Blackrock | 23.92 k | $7.15 mm |
LPL Financial | 20.00 k | $5.98 mm |
Citadel Advisors | 15.03 k | $4.43 mm |
News
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
18 Apr 24
Tenax Therapeutics: Q4 Earnings Insights
28 Mar 24
Tenax Therapeutics Q4 EPS $(11.84) Misses $(8.14) Estimate
28 Mar 24
Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
11 Mar 24
Roth MKM Reiterates Buy on Tenax Therapeutics, Maintains $30 Price Target
20 Feb 24
Press releases
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
8 Feb 24
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
7 Feb 24
Thinking about buying stock in McDonald's, Uber Technologies, Medavail, Intelligent Bio Solutions, or Tenax Therapeutics?
7 Feb 24